Clinical Trial Update: Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of ZN-d5 for relapsed or refractory AL amyloidosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• ZN-d5

Snippet

Sponsor: K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Conditions: Amyloidosis, AL Amyloidosis | Phase 1, Phase 2 | Status: COMPLETED